Rebecca Taub - 16 Jan 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Pres., R&D, and CMO, Director
Signature
/s/ Brian J. Lynch**
Issuer symbol
MDGL
Transactions as of
16 Jan 2023
Net transactions value
$0
Form type
4
Filing time
18 Jan 2023, 19:00:10 UTC
Previous filing
01 Aug 2022
Next filing
18 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +20,001 $0.000000 20,001 16 Jan 2023 Direct F1
holding MDGL Common Stock 434,758 16 Jan 2023 Direct
holding MDGL Common Stock 655,540 16 Jan 2023 By SQN, LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
F2 The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

**As attorney-in-fact for Reporting Person